BACKGROUND: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis after drug-eluting stent (DES) implantation. We compared the morphological characteristics of neointimal tissue as assessed by optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in patients treated with DES. METHODS: A total of 243 patients (250 lesions) underwent follow-up OCT and IVUS after DES implantation. RESULTS: Mean time interval from DES implantation to follow-up OCT/IVUS was 12.0 ± 9.3 (range 2.8-68.5) months. Percent neointimal hyperplasia (NIH) cross-sectional area (CSA) was calculated as (NIH CSA/stent CSA) × 100 for receiver-operating characteristic analysis of NIH detection by IVUS; the optimal cutoff value of percent NIH CSA was 14.7%, as determined by OCT (sensitivity 0.887, specificity 0.790). Neointimal hyperplasia was detected by both OCT and IVUS in 121 of 250 lesions and categorized as homogenous (OCT n = 74, IVUS n = 107), heterogeneous (OCT n = 34, IVUS n = 4), or layered (OCT n = 13, IVUS n = 10). Of the 121 NIH lesions, nonhomogenous NIH was detected in 14 (11.6%) by IVUS and 47 (38.8%) by OCT. Optical coherence tomography and IVUS assessments of NIH morphology showed a moderate correlation (P < .001, r = 0.455); however, assessments differed in 37 (30.6%) of 121 lesions. CONCLUSION: Optical coherence tomography-assessed NIH morphology might be different from that by IVUS in about 30% of the lesions that were treated with DES implantation.
BACKGROUND: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis after drug-eluting stent (DES) implantation. We compared the morphological characteristics of neointimal tissue as assessed by optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in patients treated with DES. METHODS: A total of 243 patients (250 lesions) underwent follow-up OCT and IVUS after DES implantation. RESULTS: Mean time interval from DES implantation to follow-up OCT/IVUS was 12.0 ± 9.3 (range 2.8-68.5) months. Percent neointimal hyperplasia (NIH) cross-sectional area (CSA) was calculated as (NIH CSA/stent CSA) × 100 for receiver-operating characteristic analysis of NIH detection by IVUS; the optimal cutoff value of percent NIH CSA was 14.7%, as determined by OCT (sensitivity 0.887, specificity 0.790). Neointimal hyperplasia was detected by both OCT and IVUS in 121 of 250 lesions and categorized as homogenous (OCT n = 74, IVUS n = 107), heterogeneous (OCT n = 34, IVUS n = 4), or layered (OCT n = 13, IVUS n = 10). Of the 121 NIH lesions, nonhomogenous NIH was detected in 14 (11.6%) by IVUS and 47 (38.8%) by OCT. Optical coherence tomography and IVUS assessments of NIH morphology showed a moderate correlation (P < .001, r = 0.455); however, assessments differed in 37 (30.6%) of 121 lesions. CONCLUSION: Optical coherence tomography-assessed NIH morphology might be different from that by IVUS in about 30% of the lesions that were treated with DES implantation.
Authors: Maria Mori Brooks; Robert L Frye; Saul Genuth; Katherine M Detre; Richard Nesto; Burton E Sobel; Sheryl F Kelsey; Trevor J Orchard Journal: Am J Cardiol Date: 2006-04-17 Impact factor: 2.778
Authors: James B Hermiller; Albert Raizner; Louis Cannon; Paul A Gurbel; Michael A Kutcher; S Chiu Wong; Mary E Russell; Stephen G Ellis; Roxana Mehran; Gregg W Stone Journal: J Am Coll Cardiol Date: 2005-04-19 Impact factor: 24.094
Authors: T Joseph; J Fajadet; C Jordan; B Cassagneau; J C Laborde; J P Laurent; J Marco Journal: Catheter Cardiovasc Interv Date: 1999-07 Impact factor: 2.692
Authors: D O Williams; R Holubkov; W Yeh; M G Bourassa; M Al-Bassam; P C Block; P Coady; H Cohen; M Cowley; G Dorros; D Faxon; D R Holmes; A Jacobs; S F Kelsey; S B King; R Myler; J Slater; V Stanek; H A Vlachos; K M Detre Journal: Circulation Date: 2000-12-12 Impact factor: 29.690
Authors: Andrew M Freeman; J Dawn Abbott; Alice K Jacobs; Helen A Vlachos; Faith Selzer; Warren K Laskey; Katherine M Detre; David O Williams Journal: J Interv Cardiol Date: 2006-12 Impact factor: 2.279
Authors: Suresh R Mulukutla; Helen A Vlachos; Oscar C Marroquin; Faith Selzer; Elizabeth M Holper; J Dawn Abbott; Warren K Laskey; David O Williams; Conrad Smith; William D Anderson; Joon S Lee; Vankeepuram Srinivas; Sheryl F Kelsey; Kevin E Kip Journal: JACC Cardiovasc Interv Date: 2008-04 Impact factor: 11.195
Authors: Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye Journal: Circulation Date: 2009-11-17 Impact factor: 29.690
Authors: B Stein; W S Weintraub; S P Gebhart; C L Cohen-Bernstein; R Grosswald; H A Liberman; J S Douglas; D C Morris; S B King Journal: Circulation Date: 1995-02-15 Impact factor: 29.690
Authors: Jesse W Rowley; Aloke V Finn; Patricia A French; Lisa K Jennings; Danny Bluestein; Peter L Gross; Jane E Freedman; Steven R Steinhubl; Guy A Zimmerman; Richard C Becker; Harold L Dauerman; Susan S Smyth Journal: Circ Cardiovasc Interv Date: 2012-04 Impact factor: 6.546